Clinical Trial Update: Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

This update reports a Phase 2 trial testing ipilimumab with or without high-dose recombinant interferon alfa-2b in patients with unresectable Stage III-IV melan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Interferon alfa-2b (interferon alfa-2b)
• ipilimumab (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7 | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2019-01-11